Drugs / Cyclosporin A
Cyclosporin A
also known as
CsA · cyclosporin · Ciclosprin A · cyclosporine · Cyclosporine A · Restasis · Sandimmune
targets IL2 via inhibition
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06246786 | Jul 2024 → Jun 2025 | DNA repair disease, triple-negative breast carcinoma | Virginia G. Kaklamani | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 11 trial | ||||||
| Phase 1 | NCT00001737 | May 1998 → Mar 2004 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04540926 | Sep 2020 | viral pneumonia | Institute for Social Security and Services for State Workers | Unknown | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT06802055 | Jan 2025 → Jan 2026 overdue | aplastic anemia | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT01527240 | Oct 2009 | stroke disorder | Hospices Civils de Lyon | Completed | Missed primary |
| Phase 2 | NCT00001731 | Nov 1997 → Oct 2000 | Sjogren syndrome, dry eye syndrome | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00001212 | Nov 1986 → Sep 2004 | nephrotic syndrome, systemic lupus erythematosus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02706470 | May 2016 → Feb 2018 | pregnancy loss, recurrent, 4 | Fudan University | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02203422 | Jul 2014 → Jul 2015 | autoimmune thrombocytopenia | Shandong University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01843348 | Dec 2012 → Mar 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00461825 | Jul 1998 → Feb 2007 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 45 trials · 1 missed | ||||||
| Phase 4 | NCT06525948 | Jul 2024 → Jun 2025 overdue | aplastic anemia | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05692843 | Oct 2022 → Nov 2023 | atopic eczema | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 4 | NCT04376528 | Jun → Dec 2021 | autoimmune hepatitis, primary biliary cholangitis | West China Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02370550 | Mar 2015 → Mar 2021 | Sjogren syndrome | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00956293 | Jul 2009 → Mar 2013 | — | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase not applicable5 trials | ||||||
| — | NCT06944132 | Apr → Sep 2024 | conjunctival pterygium | Benha University | Completed | No outcome recorded |
| — | NCT04451239 | Jun → Jul 2020 | keratoconjunctivitis | Ameera Gamal Abdelhameed | Unknown | No outcome recorded |
| — | NCT02147509 | Mar 2013 → Apr 2014 | Sjogren syndrome | Jinyang Li | Completed | No outcome recorded |
| — | NCT00359814 | Nov 2004 → Jun 2008 | — | Hannover Medical School | Completed | No outcome recorded |
| — | NCT00359658 | Nov 2004 → Jun 2008 | — | Hannover Medical School | Completed | No outcome recorded |
| Comparator or background therapy28 trials | ||||||
| Phase 1 | NCT00513474 Background | Jan 2008 → Feb 2013 | graft versus host disease, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +1 | Massachusetts General Hospital | Completed | Met primary |
| Phase 1 | NCT00458250 Background | Sep 2006 → Feb 2008 | acute lymphoblastic leukemia, acute myeloid leukemia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT02472054 Background | Jun 2015 → Sep 2019 | hemophagocytic syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT00303667 Background | Jan 2005 → Mar 2011 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT04688021 Background | Dec 2020 → Dec 2024 | graft versus host disease, leukemia | Yi Luo | Unknown | No outcome recorded |
| Phase 2 | NCT03192657 Background | Jul 2017 → Jun 2019 | dermatomyositis, interstitial lung disease | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02144792 Comparator | May 2013 → May 2014 | epilepsy | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01760096 Background | Jan 2013 → Jul 2016 | bone marrow failure syndrome, paroxysmal nocturnal hemoglobinuria, thrombotic disease | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT01642979 Comparator | Jul 2012 → Jul 2016 | bone marrow failure syndrome, paroxysmal nocturnal hemoglobinuria, thrombotic disease | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 2 | NCT01033656 Comparator | Dec 2005 → Mar 2010 | adult-onset Still disease | University of Helsinki | Completed | No outcome recorded |
| Phase 2 | NCT00520468 Background | Jun 2004 → Jun 2009 | myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00176865 Comparator | Aug 2002 → Aug 2012 | Chediak-Higashi syndrome, Griscelli syndrome, Langerhans cell histiocytosis, X-linked lymphoproliferative syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2/3 | NCT01238328 Background | Sep 2009 → Sep 2012 | mucopolysaccharidosis | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT06903884 Comparator | Feb 2026 → Jun 2028 expected | vernal keratoconjunctivitis | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT04945096 Background | Jul 2021 → Jul 2025 | graft versus host disease | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 3 | NCT04547049 Comparator | Sep 2020 → Apr 2026 overdue | leukemia, myelodysplastic syndrome | First Affiliated Hospital of Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03026946 Comparator | May 2017 → Jul 2022 | hand dermatosis | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 3 | NCT01766375 Background | Aug 2012 → Jan 2016 | acute myeloid leukemia | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02314312 Background | Jan 2012 → Jun 2015 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT00521924 Comparator | Jun 2007 → Apr 2008 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00114777 Comparator | Feb 2005 → May 2008 | — | Bristol-Myers Squibb | Completed | Mixed |
| Phase 3 | NCT00167583 Comparator | Nov 2004 → Dec 2014 | Behcet disease, panuveitis, retinal vasculitis | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 4 | NCT04239859 Comparator | Jan 2024 → Dec 2027 expected | psoriasis | Singapore General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04537689 Comparator | Dec 2020 → Dec 2027 expected | psoriasis | Singapore General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT03896971 Background | Nov 2019 → Dec 2020 | aplastic anemia | Safaa AA Khaled | Completed | No outcome recorded |
| — | NCT02487069 Background | Jun 2015 → Jan 2020 | acute leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Nanfang Hospital, Southern Medical University | Completed | Met primary |
| — | NCT00565669 Background | Oct 2007 → Oct 2008 | dry eye syndrome | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00003538 Background | Mar 1997 → May 2004 | cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclosporin A | “Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide,...” NCT01033656 ↗48“All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .” NCT04451239 ↗ “Patients received topical cyclosporin A (0.05%) twice daily for three months postoperatively.” NCT06944132 ↗ “The incidence of GVHD was dependent on the duration of cyclosporin A (CsA) immunosuppression.” PMID 9849691 ↗ Nov 1998 “Cyclosporin A Combined to Intravenous Thrombolysis. Multicenter Randomized Placebo-controlled” NCT01527240 ↗ “Researchers can choose cyclosporin A or tacrolimus according to patient tolerance.” NCT03192657 ↗ “P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused” NCT02144792 ↗ “Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv” NCT01238328 ↗ “0.05% CsA: 0.05% cyclosporin A” NCT02147509 ↗ |
| Known as | Ciclosprin A | “Drug: Ciclosprin A” NCT01527240 ↗ |
| Known as | CsA | “Oral Cyclosporin A (CsA) has been shown in several human trials to be effective in treating chronic uveitis.” NCT00001737 ↗6“The incidence of GVHD was dependent on the duration of cyclosporin A (CsA) immunosuppression.” PMID 9849691 ↗ Nov 1998 “Group A: CsA + Azathioprine(1 to 2 mg/kg/day)” NCT00461825 ↗ “Cyclosporin A(CsA)+glucocorticoid” NCT02370550 ↗ “0.05% CsA: 0.05% cyclosporin A” NCT02147509 ↗ “Cyclosporin A (CSA)” NCT02472054 ↗ “Cyclosporin A (CsA)” NCT06802055 ↗ |
| Known as | cyclosporin | “Previous studies in humans have shown that, taken by mouth, the drug cyclosporin is effective in treating chronic uveitis.” NCT00001737 ↗1“one will take a cyclosporin 0.1% eye drop emulsion” NCT00001731 ↗ |
| Known as | cyclosporine | “patients received either an IV bolus injection of 2.0 mg/kg cyclosporine (Sandimmune, Novartis) or placebo.” PMID 25948727 ↗ May 2015 |
| Known as | Cyclosporine A | “Cyclosporine A has long been known to suppress T cell responses by inhibiting the production of IL-2” PMID 30880061 ↗ Mar 2019 |
| Known as | Restasis | “Cyclosporin A (Restasis®, Allergan, Irvine, CA) has been shown to significantly reduce the number of activated T-lymphocytes within the conjunctiva” NCT00565669 ↗ |
| Known as | Sandimmune | “patients received either an IV bolus injection of 2.0 mg/kg cyclosporine (Sandimmune, Novartis) or placebo.” PMID 25948727 ↗ May 2015 |
| Action | Inhibit | “Cyclosporine A has long been known to suppress T cell responses by inhibiting the production of IL-2” PMID 30880061 ↗ Mar 2019 |
| Route | Oral | “oral cyclosporin A” NCT00001212 ↗ |
| Target | IL2 | “Cyclosporine A has long been known to suppress T cell responses by inhibiting the production of IL-2” PMID 30880061 ↗ Mar 2019 |